Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images.
暂无分享,去创建一个
B. Erickson | V. Torri | A. Bizzi | M. Cadioli | D. Aquino | P. Vitali | M. Caulo | A. Castellano | G. Grillea | V. Cuccarini | M. Grimaldi | N. Anzalone | G. Conte | M. Terreni | Antonella Costa
[1] Gian Marco Conte,et al. Reproducibility of dynamic contrast-enhanced MRI and dynamic susceptibility contrast MRI in the study of brain gliomas: a comparison of data obtained using different commercial software , 2017, La radiologia medica.
[2] R. Thornhill,et al. Correlation of Tumor Immunohistochemistry with Dynamic Contrast-Enhanced and DSC-MRI Parameters in Patients with Gliomas , 2016, American Journal of Neuroradiology.
[3] C. Zimmer,et al. Multiparametric MRI-based differentiation of WHO grade II/III glioma and WHO grade IV glioblastoma , 2016, Scientific Reports.
[4] Martin Sill,et al. Radiogenomics of Glioblastoma: Machine Learning-based Classification of Molecular Characteristics by Using Multiparametric and Multiregional MR Imaging Features. , 2016, Radiology.
[5] A. Falini,et al. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis. , 2016, European journal of radiology.
[6] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[7] S. J. Mills,et al. Mitotic Activity in Glioblastoma Correlates with Estimated Extravascular Extracellular Space Derived from Dynamic Contrast-Enhanced MR Imaging , 2016, American Journal of Neuroradiology.
[8] G. Liberman,et al. Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI , 2016, Journal of Neuro-Oncology.
[9] Zachary S. Kelm,et al. Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma , 2015, American Journal of Neuroradiology.
[10] R. Thornhill,et al. Comparison of the Diagnostic Accuracy of DSC- and Dynamic Contrast-Enhanced MRI in the Preoperative Grading of Astrocytomas , 2015, American Journal of Neuroradiology.
[11] Kyung K. Peck,et al. Dynamic contrast enhanced T1 MRI perfusion differentiates pseudoprogression from recurrent glioblastoma , 2015, Journal of Neuro-Oncology.
[12] M Wintermark,et al. ASFNR Recommendations for Clinical Performance of MR Dynamic Susceptibility Contrast Perfusion Imaging of the Brain , 2015, American Journal of Neuroradiology.
[13] À. Rovira,et al. Pixel-by-Pixel Comparison of Volume Transfer Constant and Estimates of Cerebral Blood Volume from Dynamic Contrast-Enhanced and Dynamic Susceptibility Contrast-Enhanced MR Imaging in High-Grade Gliomas , 2015, American Journal of Neuroradiology.
[14] Zachary S. Kelm,et al. Variability and accuracy of different software packages for dynamic susceptibility contrast magnetic resonance imaging for distinguishing glioblastoma progression from pseudoprogression , 2015, Journal of medical imaging.
[15] Sumei Wang,et al. Glioma grading by microvascular permeability parameters derived from dynamic contrast-enhanced MRI and intratumoral susceptibility signal on susceptibility weighted imaging , 2015, Cancer Imaging.
[16] M. Essig,et al. Principles of T2*‐weighted dynamic susceptibility contrast MRI technique in brain tumor imaging , 2015, Journal of magnetic resonance imaging : JMRI.
[17] M. V. Valdés Hernández,et al. Assessment of blood–brain barrier disruption using dynamic contrast-enhanced MRI. A systematic review , 2014, NeuroImage: Clinical.
[18] Egill Rostrup,et al. Discrimination between glioma grades II and III in suspected low-grade gliomas using dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging: a histogram analysis approach , 2014, Neuroradiology.
[19] A. Bjørnerud,et al. Sampling requirements in DCE‐MRI based analysis of high grade gliomas: Simulations and clinical results , 2013, Journal of magnetic resonance imaging : JMRI.
[20] H. Larsson,et al. Evaluation of dynamic contrast-enhanced T1-weighted perfusion MRI in the differentiation of tumor recurrence from radiation necrosis , 2013, Neuroradiology.
[21] Max Wintermark,et al. Perfusion MRI: the five most frequently asked clinical questions. , 2013, AJR. American journal of roentgenology.
[22] Douglas C. Miller,et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. , 2008, Radiology.
[23] R M Weisskoff,et al. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. , 2006, AJNR. American journal of neuroradiology.
[24] M. Bastin,et al. Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma. , 2006, AJNR. American journal of neuroradiology.
[25] Geoff J M Parker,et al. Is volume transfer coefficient (K(trans)) related to histologic grade in human gliomas? , 2005, AJNR. American journal of neuroradiology.
[26] Glyn Johnson,et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. , 2003, AJNR. American journal of neuroradiology.
[27] B. Rosen,et al. Early changes measured by magnetic resonance imaging in cerebral blood flow, blood volume, and blood-brain barrier permeability following dexamethasone treatment in patients with brain tumors. , 1999, Journal of neurosurgery.
[28] E P Frenkel,et al. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. , 1982, Proceedings of the National Academy of Sciences of the United States of America.
[29] Diana Delgado,et al. MR perfusion-weighted imaging in the evaluation of high-grade gliomas after treatment: a systematic review and meta-analysis , 2017, Neuro-oncology.
[30] S. Heiland,et al. Evaluation of dynamic contrast-enhanced MRI derived microvascular permeability in recurrent glioblastoma treated with bevacizumab , 2014, Journal of Neuro-Oncology.
[31] Dafna Ben Bashat,et al. Classification of tumor area using combined DCE and DSC MRI in patients with glioblastoma , 2014, Journal of Neuro-Oncology.